At-Risk
Moderna’s COVID Vaccine Wins FDA Approval for At-Risk Young Children
Moderna; FDA approval; COVID vaccine; children; at-risk; Spikevax; underlying conditions; full approval
Moderna Wins Expanded FDA Approval for RSV Vaccine in At-Risk Younger Adults
Moderna; RSV vaccine; FDA approval; mRESVIA; at-risk adults; 18 to 59 years; expanded label; chronic health conditions
FDA Expands Approval of GSK’s RSV Vaccine to Include At-Risk Adults Aged 50-59
RSV vaccine, GSK, FDA approval, at-risk adults, respiratory syncytial virus, Arexvy